Mirum (MIRM) news
Recent news
Mirum Pharmaceuticals, Inc.: Citigroup raises target price to $184 from $160
AInvest Wire · 1d agoMirum Pharmaceuticals, Inc.: H.C. Wainwright raises target price to $200 from $195
H.C. Wainwright has revised its price target for Mirum Pharmaceuticals, Inc. (NASDAQ: MRUM), raising it to $200 from the previous $195, as of October 12, 2026. The adjustment reflects the firm’s updated assessment of the company’s financial outlook and market positioning. The new target suggests a…
AInvest Wire · 2d agoMirum to file SNA for Livmarli in 1H 2027
Mirum Pharmaceuticals Inc. has announced its intention to file a Supplemental New Drug Application (SNA) for Livmarli (maralixibat) in the first half of 2027, according to internal planning and regulatory strategy . The SNA is expected to expand the therapeutic indications for the drug, building on…
AInvest Wire · 2d agoMirum Pharma shares extend gain to 13% after study data
AInvest Wire · 2d agoMirum Pharmaceuticals - Plans U.S. SNDA submission in first half of 2027 based on expand results
Mirum Pharmaceuticals has announced plans to submit a U.S. Supplemental New Drug Application (SNDA) in the first half of 2027 for its investigational therapy, OCA (Ocaliva), based on expanded clinical results. The company stated that the submission will seek to broaden the approved use of OCA to…
AInvest Wire · 2d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.